Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 188,465 |
Total Actual Volume | 2,232,233 |
Short Trends | |
---|---|
Cover Days | 9 |
Short Days | 4 |
No Change Days | 7 |
Averages | |
---|---|
Average Short Volume | 9,423 |
Average Short Percentage | 36.05% |
Is there a HEB Short Squeeze or Breakout about to happen?
See the HEB Short Analysis for free Sign up or Login
Powered by Squeeze Report
Stock Date | Open Price | Close Price | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
2019-08-30 | 1.97 | 1.80 | 1.97 | 1.78 | 14,684 | 185 | 7.7244 |
2019-08-29 | 1.938 | 1.81 | 1.938 | 1.78 | 31,067 | 1,512 | 29.9881 |
2019-08-28 | 1.893 | 1.86 | 1.9002 | 1.81 | 11,903 | 47 | 2.4165 |
2019-08-27 | 1.87 | 1.87 | 1.99 | 1.83 | 38,608 | 509 | 22.4427 |
2019-08-26 | 1.92 | 1.90 | 2.00 | 1.90 | 20,549 | 2,404 | 67.6231 |
2019-08-23 | 1.90 | 1.93 | 2.06 | 1.8965 | 57,868 | 1,802 | 12.2970 |
2019-08-22 | 1.92 | 1.9223 | 1.9599 | 1.8301 | 32,984 | 2,445 | 33.4611 |
2019-08-21 | 1.92 | 1.9196 | 1.98 | 1.79 | 35,505 | 2,693 | 57.2005 |
2019-08-20 | 1.94 | 1.9201 | 1.9946 | 1.90 | 36,024 | 3,713 | 54.9342 |
2019-08-19 | 1.88 | 1.93 | 2.07 | 1.7906 | 70,320 | 5,274 | 35.8995 |
2019-08-16 | 2.00 | 1.89 | 2.00 | 1.705 | 89,596 | 10,483 | 48.7695 |
2019-08-15 | 2.00 | 1.90 | 2.07 | 1.82 | 58,505 | 3,156 | 42.4650 |
2019-08-14 | 2.00 | 1.85 | 2.00 | 1.80 | 59,333 | 802 | 5.8065 |
2019-08-13 | 1.84 | 1.89 | 1.959 | 1.81 | 47,364 | 3,899 | 39.4436 |
2019-08-12 | 2.02 | 1.86 | 2.02 | 1.69 | 70,256 | 2,452 | 35.3518 |
2019-08-09 | 2.19 | 1.99 | 2.19 | 1.91 | 176,184 | 14,415 | 28.7071 |
2019-08-08 | 2.37 | 2.22 | 2.44 | 2.10 | 1,238,854 | 100,531 | 39.9651 |
2019-08-07 | 2.06 | 2.07 | 2.11 | 2.05 | 47,079 | 19,183 | 85.2502 |
2019-08-06 | 2.15 | 2.05 | 2.15 | 2.00 | 37,626 | 3,078 | 27.7647 |
2019-08-05 | 2.20 | 2.09 | 2.2365 | 2.02 | 57,924 | 9,882 | 43.5657 |
Hemispherx BioPharma Inc. Company Name:
HEB Stock Symbol:
NYSE Market:
Hemispherx BioPharma Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic...
OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces the filing of its report 10Q for the ...
OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB ) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent ovar...